Impact of metastatic estrogen receptor and progesterone receptor status on survival

被引:0
|
作者
Elyse E. Lower
Eleanor L. Glass
Deborah A. Bradley
Robbin Blau
Sue Heffelfinger
机构
[1] University of Cincinnati College of Medicine,Department of Internal Medicine
[2] Oncology–Hematology Care,undefined
[3] University of Cincinnati Medical Center,undefined
来源
Breast Cancer Research and Treatment | 2005年 / 90卷
关键词
Breast cancer; estrogen receptors; hormone therapy; metastatic hormone receptors;
D O I
暂无
中图分类号
学科分类号
摘要
Hormone responsive breast cancer is usually determined by the presence of estrogen receptors (ER) or progesterone receptors (PR) on primary invasive breast cancers. Adjuvant and metastatic hormone therapy are recommended based on primary ER and PR determination. Little information is available to determine if primary hormone receptors correlate with metastatic disease and if survival is influenced by metastatic receptor status. We retrospectively compared primary to metastatic tumor ER and PR content from 200 metastatic breast cancer patients. ER and PR analyses were available in both primary and metastatic disease in 200 and 173 patients, respectively. There was a correlation between both the ER and PR in the primary and metastatic lesion (p < 0.001). However, in 60 of 200 (30%) patients, discordance between primary and metastatic ER was noted. Tumors from 68 of 173 (39.3%) showed discordance for PR. In 39 (19.5%) patients, the ER primary status was positive and metastatic status was negative and in 21 (10.5%) patients, the primary status was negative and metastatic status was positive. Survival from the time of metastatic diagnosis was calculated. Those patients with ER positive primary and metastatic tumors (Positive/Positive) or only the metastatic lesion (Negative/Positive) had similar median survival (1131 and 1111 days, respectively). However, patients with tumors that changed from positive primary to negative metastasis (Positive/Negative) experienced significantly shorter median survival (669 days, p < 0.05). Likewise, median survival (580 days) was significantly shorter for patients with primary and metastasis ER negative (Negative/Negative, p < 0.001) compared to Positive/Positive (p < 0.001) or compared to Negative/Positive (p < 0.02). The changes in PR status were not associated with a change in survival. We found a significant discordance between hormone receptor content of primary versus metastatic breast cancer. The ER status of the metastatic lesion was a better predictor of survival. Therefore, optimal metastatic treatment cannot be determined solely on primary ER and PR analysis.
引用
收藏
页码:65 / 70
页数:5
相关论文
共 50 条
  • [1] Impact of metastatic estrogen receptor and progesterone receptor status on survival
    Lower, EE
    Glass, EL
    Bradley, DA
    Blau, R
    Heffelfinger, S
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 90 (01) : 65 - 70
  • [2] Impact of progesterone receptor (PR) status on survival of estrogen receptor (ER) positive women with invasive breast cancer (IBC)
    Ingle, A. M.
    Kumar, P.
    Dagen, T.
    Day, K.
    Baney, B.
    Galley, A. S.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S256 - S257
  • [3] Estrogen receptor and progesterone receptor status: differences between primary and metastatic breast cancer.
    Glass, EL
    Heffelfinger, S
    Blau, R
    Lower, EE
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S60 - S60
  • [4] Estrogen and progesterone receptor status and disease specific survival in skull base chordomas
    Keel, SB
    Koerner, FC
    Efird, JT
    Bhan, AK
    Rosenberg, AE
    LABORATORY INVESTIGATION, 1996, 74 (01) : 24 - 24
  • [5] The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas*
    Moreira-Dinzey, Jennifer
    Zhan, Haiying
    Rozenblit, Mariya
    Krishnamurti, Uma
    Harigopal, Malini
    Zhong, Minghao
    Liang, Yuanxin
    HUMAN PATHOLOGY, 2023, 137 : 56 - 62
  • [6] Patterns of disease spread in metastatic breast carcinoma: Influence of estrogen and progesterone receptor status
    Maki, DD
    Grossman, RI
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2000, 21 (06) : 1064 - 1066
  • [7] Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer
    Umekita, Y
    Sagara, Y
    Yoshida, H
    JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (01): : 27 - 32
  • [8] Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients
    Yao, Nan
    Song, Zhenchuan
    Wang, Mule
    Yang, Shan
    Song, Heng
    JOURNAL OF BREAST CANCER, 2017, 20 (02) : 160 - 169
  • [9] Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer
    Amy M. Fowler
    Kelley Salem
    Michael DeGrave
    Irene M. Ong
    Shane Rassman
    Ginny L. Powers
    Manoj Kumar
    Ciara J. Michel
    Aparna M. Mahajan
    Hormones and Cancer, 2020, 11 : 63 - 75
  • [10] Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer
    Fowler, Amy M.
    Salem, Kelley
    DeGrave, Michael
    Ong, Irene M.
    Rassman, Shane
    Powers, Ginny L.
    Kumar, Manoj
    Michel, Ciara J.
    Mahajan, Aparna M.
    HORMONES & CANCER, 2020, 11 (02): : 63 - 75